Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR), 2015.

November 11, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with corresponding circulars and notifications issued thereunder, it is hereby informed to you that Company executed a Shareholders’ Agreement (“SHA”) with IQGEN-X Pharma Private Limited (“IQGEN-X”) and Continuing Existing Shareholders of (‘CES’) IQGEN-X, to record their mutual understanding with respect to, amongst others, inter se rights and obligations by virtue of their shareholding and certain other matters as mentioned in the SHA. The details of SHA, as required under Regulation 30 of the Listing Regulations read with Schedule III thereto and the applicable SEBI Master Circular are enclosed as Annexure A. You are requested to kindly takes note of the same. This is for your information and records Thanking You, Your Sincerely, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl: As above Alivus Life Sciences Limited ( formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumba–i 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Annexure A The details as required in terms of Regulation 30 and Regulation 5 and 5A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 are as under: - Sr. Particulars Details 1. Name(s) of parties with whom the Agreement has entered by and between Alivus Life agreement is entered Sciences Limited (“Company”), Dr. Mandar Kodgule & Dr. Yogita Kodgule (collectively ‘Continuing Existing Shareholders’ (‘CES’) and IQGEN-X Pharma Private Limited. 2. Purpose of entering into the To record Shareholders mutual understanding with agreement respect to, amongst others, inter se rights and obligations by virtue of their shareholding and certain other matters as mentioned in the SHA. 3. Shareholding, if any, in the entity The Company had entered into share purchase with whom the agreement is agreement to acquire 76% stake in IQGEN-X Pharma executed Private Limited. 4. Significant terms of the • The Company has an option to Buy the remaining agreement (in brief) special rights 24% of CES shareholding at the end of 5 years from like right to appoint directors, first the date of closing of this transaction at a pre right to share subscription in case agreed Benchmark price defined in the SHA of issuance of shares, right to • Board Composition: 3 Directors (2 from the restrict any change in capital Company, 1 from CES). structure etc. • No transfer of shares except as permitted by the Agreement 5. extent and the nature of impact No impact on management or control of the listed on management or control of the entity listed entity 6. details and quantification of the Not Applicable restriction or liability imposed upon the listed entity 7. Whether, the said parties are No related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship 8.. Whether the transaction would No. However, the Company has entered into share fall within related party purchase agreement to acquire 76% stake in IQGEN-X transactions? If yes, whether the Pharma Private Limited. same is done at “arm’s length”; 9. In case of issuance of shares to Not Applicable the parties, details of issue price, class of shares issued 10. Any other disclosures related to The Company has right to appoint majority Directors such agreements, viz., details of in IQGEN-X. nominee on the board of directors of the listed entity, No potential conflict of interest arising out of this SHA. potential conflict of interest arising out of such agreements, etc. 11. in case of termination or Not Applicable amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.